Roche Holding AG

Report azionario SWX:ROG

Capitalizzazione di mercato: CHF 257.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Roche Holding Gestione

Criteri Gestione verificati 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Thomas Schinecker

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO3yrs
Proprietà del CEO0.0004%
Durata media del management6yrs
Durata media del Consiglio di amministrazione6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Aggiornamento della narrazione • Mar 21

ROG: 2026 Clinical Catalysts And Obesity Data Will Drive Upside Potential

Analysts now place fair value for Roche Holding at CHF 363.47. This is a modest adjustment supported by mixed recent research that highlights softer revenue growth and profit margin assumptions, a higher future P/E, and a wider spread of Street price targets ranging from CHF 325 to CHF 390, alongside ratings that span from Neutral to Buy.
Aggiornamento della narrazione • Mar 07

ROG: Genomics Pricing And Cautious Pipeline Outlook Will Constrain Future Upside

The analyst fair value estimate for Roche Holding has been raised from CHF 230.00 to CHF 262.39, as analysts factor in updated assumptions for revenue growth, profit margins, and a lower future P/E multiple, alongside recent Street price target increases and more constructive views on the pipeline and diagnostics pricing. Analyst Commentary Recent research has highlighted a mixed but generally more constructive tone around Roche, with fresh attention on pricing decisions, the pipeline, and relative positioning versus peers in diagnostics and genomics.
Aggiornamento della narrazione • Feb 21

ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead

Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
Aggiornamento della narrazione • Feb 07

ROG: 2026 Clinical Pipeline And Execution Progress Will Drive Future Rerating

Analysts have nudged their fair value estimate for Roche Holding slightly higher to CHF 428, citing a mix of updated assumptions around revenue growth, profit margins, discount rates and future P/E multiples, along with recent upward moves in Street price targets and more constructive research coverage. Analyst Commentary Bullish analysts have become more constructive on Roche in recent months, with several research notes pointing to upgraded ratings, refreshed price targets and improving sentiment around the pipeline and execution.
Articolo di analisi • Feb 03

Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year

As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...
Nuova narrazione • Feb 01

Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond

About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.
Aggiornamento della narrazione • Jan 23

ROG: 2026 Clinical Milestones And Execution Progress Will Drive Future Rerating

Analysts have raised their price expectations for Roche Holding, citing updated assumptions that include improved revenue growth, a slightly lower projected profit margin, and a modestly reduced future P/E multiple. These changes are supported by recent rating upgrades and positive commentary on clinical catalysts and the operational outlook.
Aggiornamento della narrazione • Jan 09

ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution

Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.
Aggiornamento della narrazione • Dec 17

ROG: Pipeline Data And Digital Execution Will Shape Balanced Risk Reward Ahead

Analysts have nudged their fair value estimate for Roche Holding higher, lifting the target by about CHF 11.50 to reflect slightly stronger long term revenue growth and margin assumptions supported by recent positive readthroughs from partners, incremental pipeline visibility, and a modest firming in Street price targets. Analyst Commentary Bullish analysts emphasize that recent partner updates and pipeline milestones are incrementally improving sentiment on Roche, supporting the view that medium term growth and margin visibility are strengthening despite a still mixed backdrop.
Aggiornamento della narrazione • Dec 03

ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead

Analysts modestly raise their price target on Roche Holding, reflecting an updated fair value estimate of approximately CHF 312 from about CHF 305 as they factor in slightly stronger long term revenue growth, improving margins, and supportive readthroughs from recent pipeline and partnership developments. Analyst Commentary Recent Street commentary around Roche continues to frame the company as a strategically important player in oncology, ophthalmology, and digital enablement, while also highlighting competitive and execution risks that temper upside expectations.
Aggiornamento della narrazione • Nov 19

ROG: Sector Pressures And Mixed Trial Results Will Shape Performance Ahead

Roche Holding’s analyst price target has been raised by CHF 10 to CHF 255. Analysts cite moderate adjustments to fair value estimates, along with continued caution regarding recent trial outcomes and sector dynamics.
Articolo di analisi • Aug 20

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

SWX:ROG 1 Year Share Price vs Fair Value Explore Roche Holding's Fair Values from the Community and select yours With a...
Articolo di analisi • Jun 24

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Nuova narrazione • Feb 04

Roche Holding will see a 4.2576% revenue growth shaking the market

### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
User avatar
Nuova narrazione • Feb 02

Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025

Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Thomas Schinecker rispetto agli utili di Roche Holding?
DataCompenso totaleStipendioUtili della società
Dec 31 2025n/an/a

CHF 13b

Sep 30 2025n/an/a

CHF 11b

Jun 30 2025n/an/a

CHF 9b

Mar 31 2025n/an/a

CHF 9b

Dec 31 2024n/an/a

CHF 8b

Sep 30 2024n/an/a

CHF 9b

Jun 30 2024n/an/a

CHF 11b

Mar 31 2024n/an/a

CHF 11b

Dec 31 2023n/an/a

CHF 11b

Sep 30 2023n/an/a

CHF 11b

Jun 30 2023n/an/a

CHF 11b

Mar 31 2023n/an/a

CHF 12b

Dec 31 2022CHF 5mCHF 1m

CHF 12b

Sep 30 2022n/an/a

CHF 14b

Jun 30 2022n/an/a

CHF 15b

Mar 31 2022n/an/a

CHF 14b

Dec 31 2021CHF 4mCHF 1m

CHF 14b

Sep 30 2021n/an/a

CHF 14b

Jun 30 2021n/an/a

CHF 14b

Mar 31 2021n/an/a

CHF 14b

Dec 31 2020CHF 4mCHF 879k

CHF 14b

Sep 30 2020n/an/a

CHF 14b

Jun 30 2020n/an/a

CHF 13b

Mar 31 2020n/an/a

CHF 13b

Dec 31 2019CHF 2mCHF 609k

CHF 13b

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Thomas sia ragionevole rispetto ad aziende di dimensioni simili nel mercato Swiss.

Compensazione vs guadagni: La retribuzione di Thomas è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Thomas Schinecker (50 yo)

3yrs
Mandato
CHF 5,335,592
Compensazione

Dr. Thomas Schinecker is Chairman of the Board of Roche Holdings, Inc. from March 14, 2023. Dr. Schinecker is Director since March 27, 2025 at Chugai Pharmaceutical Co., Ltd. He serves as Chairman of the B...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Severin Schwan
Executive Chairman13yrsCHF 11.48m0.045%
CHF 115.3m
Thomas Schinecker
Group Chief Executive Officer3yrsCHF 5.34m0.00045%
CHF 1.2m
Alan Hippe
Chief Financial Officer14.9yrsCHF 6.05m0.0066%
CHF 17.1m
Bruno Eschli
Head of Investor Relationsno dataNessun datoNessun dato
Claudia Bockstiegel
General Counsel5.9yrsNessun datoNessun dato
Pascale Schmidt
Chief Compliance Officer6.2yrsNessun datoNessun dato
Nina Schwab-Hautzinger
Head of Group Communicationsless than a yearNessun datoNessun dato
Maria Cristina Wilbur
Chief People Officer10yrsCHF 4.25m0.0022%
CHF 5.6m
Nicolas Dunant
Head of Group Media Relationsno dataNessun datoNessun dato
Boris L. Zaitra
Head of Corporate Business Developmentno dataNessun datoNessun dato
Cristin Hubbard
Senior Vice President of Immunologyno dataNessun datoNessun dato
Sascha Fauser
Global Head of Ophthalmology Roche pREDno dataNessun datoNessun dato
6.0yrs
Durata media
55.5yo
Età media

Gestione esperta: Il team dirigenziale di ROG è esperto e expertise (durata media dell'incarico 6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Severin Schwan
Executive Chairman13yrsCHF 11.48m0.045%
CHF 115.3m
Ulf Schneider
Director3yrsNessun dato0.00063%
CHF 1.6m
Andre Hoffmann
Independent Vice Chairman30.2yrsCHF 400.00k3.54%
CHF 9.1b
Patrick Frost
Independent Non Executive Director6yrsCHF 360.00k0.00050%
CHF 1.3m
Richard Lifton
Non-Executive Independent Director11.2yrsCHF 346.71k0%
CHF 0
Anita Hauser
Non-Executive Independent Director9yrsCHF 336.16k0.00059%
CHF 1.5m
Lubomira Rochet
Directorno dataNessun datoNessun dato
Jorg Duschmale
Non-Executive Independent Director6yrsCHF 394.67kNessun dato
Akiko Iwasaki
Director3yrsNessun datoNessun dato
Jemilah Mahmood
Independent Non-Executive Director4yrsCHF 272.50kNessun dato
6.0yrs
Durata media
57.5yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ROG sono considerati esperti (durata media dell'incarico 6 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/03/16 20:15
Prezzo dell'azione a fine giornata2026/03/16 00:00
Utili2025/12/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Roche Holding AG è coperta da 44 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
John StaszakArgus Research Company
Gerhard SchwarzBaader Helvea Equity Research
Mark PurcellBarclays